ArticleAnnals of translational medicine2018
A case of osimertinib-resistant lung adenocarcinoma responded effectively to alternating therapy.
Haruki Hirakawa et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papercites it